253 related articles for article (PubMed ID: 20465837)
1. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.
Sadikovic B; Thorner P; Chilton-Macneill S; Martin JW; Cervigne NK; Squire J; Zielenska M
BMC Cancer; 2010 May; 10():202. PubMed ID: 20465837
[TBL] [Abstract][Full Text] [Related]
2. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Martin JW; Chilton-MacNeill S; Koti M; van Wijnen AJ; Squire JA; Zielenska M
PLoS One; 2014; 9(5):e95843. PubMed ID: 24835790
[TBL] [Abstract][Full Text] [Related]
3. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.
Roos A; Satterfield L; Zhao S; Fuja D; Shuck R; Hicks MJ; Donehower LA; Yustein JT
Br J Cancer; 2015 Nov; 113(9):1289-97. PubMed ID: 26528706
[TBL] [Abstract][Full Text] [Related]
4. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
He L; Yang H; Huang J
BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
[TBL] [Abstract][Full Text] [Related]
5. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.
Kurek KC; Del Mare S; Salah Z; Abdeen S; Sadiq H; Lee SH; Gaudio E; Zanesi N; Jones KB; DeYoung B; Amir G; Gebhardt M; Warman M; Stein GS; Stein JL; Lian JB; Aqeilan RI
Cancer Res; 2010 Jul; 70(13):5577-86. PubMed ID: 20530675
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.
Li C; Zhang S; Qiu T; Wang Y; Ricketts DM; Qi C
Cancer Biol Ther; 2019; 20(4):413-422. PubMed ID: 30489194
[TBL] [Abstract][Full Text] [Related]
7. Expression profiles of osteosarcoma that can predict response to chemotherapy.
Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
[TBL] [Abstract][Full Text] [Related]
8. Wnt/β-Catenin Signaling Activates Expression of the Bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types.
Vega OA; Lucero CMJ; Araya HF; Jerez S; Tapia JC; Antonelli M; Salazar-Onfray F; Las Heras F; Thaler R; Riester SM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2017 Nov; 118(11):3662-3674. PubMed ID: 28370561
[TBL] [Abstract][Full Text] [Related]
9. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma.
Yang J; Zhao L; Tian W; Liao Z; Zheng H; Wang G; Chen K
BMC Med Genomics; 2013 Dec; 6():56. PubMed ID: 24330824
[TBL] [Abstract][Full Text] [Related]
10. Developmental pathways hijacked by osteosarcoma.
Mortus JR; Zhang Y; Hughes DP
Adv Exp Med Biol; 2014; 804():93-118. PubMed ID: 24924170
[TBL] [Abstract][Full Text] [Related]
11. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.
Dalla-Torre CA; Yoshimoto M; Lee CH; Joshua AM; de Toledo SR; Petrilli AS; Andrade JA; Chilton-MacNeill S; Zielenska M; Squire JA
BMC Cancer; 2006 Oct; 6():237. PubMed ID: 17022822
[TBL] [Abstract][Full Text] [Related]
12. RUNX2 (6p21.1) amplification in osteosarcoma.
Gupta S; Ito T; Alex D; Vanderbilt CM; Chang JC; Islamdoust N; Zhang Y; Nafa K; Healey J; Ladanyi M; Hameed MR
Hum Pathol; 2019 Dec; 94():23-28. PubMed ID: 31669178
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway.
Jia F; Zhang Z; Zhang X
J Cell Biochem; 2019 Apr; 120(4):6420-6430. PubMed ID: 30484892
[TBL] [Abstract][Full Text] [Related]
14. RUNX2 expression in developing human bones and various bone tumors.
Sugawara M; Kato N; Tsuchiya T; Motoyama T
Pathol Int; 2011 Oct; 61(10):565-71. PubMed ID: 21951664
[TBL] [Abstract][Full Text] [Related]
15. The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines.
Lucero CM; Vega OA; Osorio MM; Tapia JC; Antonelli M; Stein GS; van Wijnen AJ; Galindo MA
J Cell Physiol; 2013 Apr; 228(4):714-23. PubMed ID: 22949168
[TBL] [Abstract][Full Text] [Related]
16. MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2.
Xie Y; Sun W; Deng Z; Zhu X; Hu C; Cai L
Sci Rep; 2017 Oct; 7(1):13388. PubMed ID: 29042587
[TBL] [Abstract][Full Text] [Related]
17. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma.
Iwata S; Tatsumi Y; Yonemoto T; Araki A; Itami M; Kamoda H; Tsukanishi T; Hagiwara Y; Kinoshita H; Ishii T; Nagase H; Ohira M
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036394
[TBL] [Abstract][Full Text] [Related]
18. Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma.
Salas S; Jiguet-Jiglaire C; Campion L; Bartoli C; Frassineti F; Deville JL; Maues De Paula A; Forest F; Jézéquel P; Gentet JC; Bouvier C
BMC Cancer; 2014 Aug; 14():606. PubMed ID: 25146150
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma.
Won KY; Park HR; Park YK
Tumori; 2009; 95(3):311-6. PubMed ID: 19688969
[TBL] [Abstract][Full Text] [Related]
20. [P-glycoprotein expression in osteosarcoma].
Pösl M; Grahl K; Amling M; Werner M; Ritzel H; Stenzel I; Hentz M; Winkler K; Delling G
Pathologe; 1996 Jan; 17(1):50-5. PubMed ID: 8685096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
